
Evidence analysis
Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 6, Status: Authorised
What is established Spevigo (active substance spesolimab) is a medicine authorized in the European Union for the prevention and treatment of flare-ups of generalised pustular psoriasis (GPP), an inflammatory skin disease characterized by widespread pustules. It is approved…
Read →
Evidence analysis
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026
CHMP November 2026 Meeting: New Medicine Recommendations and Therapeutic Extensions In November 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) conducted its regular meeting and issued a series of recommendations concerning new medicines…
Read →
Evidence analysis
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 10 November 2026, 09:30 (CET) to 10 November 2026, 13:00 (CET)
Evidence Dossier: EU Medicine Shortages SPOC Working Party Meeting, November 2026 What is established In November 2026, the European Medicines Agency (EMA) convened an online meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party. The…
Read →
Evidence analysis
Mandate and objectives for the Working Group of the MSSG on critical medicine supply security
What is established Ensuring the continuous supply of critical medicines is recognized as a key component of healthcare system resilience. Disruptions in the availability of essential drugs can have serious consequences for patient care, public health, and emergency…
Read →
Evidence analysis
Effectiveness of pneumococcal vaccination campaigns in humanitarian settings: A modelling study
Effectiveness of Pneumococcal Vaccination Campaigns in Humanitarian Settings: A Research Analysis This analysis examines a recent modelling study published in PLOS Medicine that evaluates the potential impact of pneumococcal conjugate vaccine (PCV) campaigns in humanitarian crisis settings. The…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 24, Status: Authorised
Evidence Dossier: Enhertu (trastuzumab deruxtecan) – European Medicines Agency Report Analysis What is established Enhertu, whose active substance is trastuzumab deruxtecan, is authorized in the European Union for treating various types of cancer characterized by expression of the…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Ganirelix Gedeon Richter, ganirelix, Date of authorisation: 15/07/2022, Revision: 1, Status: Authorised
What is established Ganirelix Gedeon Richter is a generic medicine authorized in the European Union since July 15, 2022. It contains the active substance ganirelix and is primarily used to prevent premature ovulation in women undergoing fertility treatment…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 31, Status: Authorised
What is established Flixabi is a biosimilar medicine containing infliximab, a monoclonal antibody targeting tumour necrosis factor-alpha (TNF-alpha), an inflammatory protein elevated in conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.…
Read →
Evidence analysis
Rethinking psychosocial rehabilitation in mental health
Rethinking Psychosocial Rehabilitation in Mental Health: An Evidence Overview This evidence dossier summarizes key findings and considerations from a 2026 article published in PLOS Medicine that addresses psychosocial rehabilitation in mental health care. It reviews the current state,…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Trisenox, arsenic trioxide, Date of authorisation: 05/03/2002, Revision: 34, Status: Authorised
What is established Trisenox, containing the active substance arsenic trioxide, is an approved medicine in the European Union for treating acute promyelocytic leukaemia (APL), a rare subtype of leukaemia characterized by a specific genetic translocation affecting white blood…
Read →